IP Library Granted Patent US 10,344,265
Granted Patent B2
US 10,344,265 · App. 15/692,518 · Granted Jul 9, 2019

Sustained polypeptide expression from synthetic, modified RNAs and uses thereof

Inventors: Derrick Rossi (Roslindale, MA); Luigi Warren (Boston, MA)
Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
C12N5/0696C07K14/435C12N15/11C12N15/111C12N2310/14C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,344,265
App. No.
15/692,518
Granted
Jul 9, 2019
Kind
B2
Abstract

Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.

Claims (6)

1. A method of making induced pluripotent stem cells, the method comprising contacting mammalian somatic cells in vitro with synthetic, modified RNAs encoding OCT4, SOX2, and KLF4 at least three times, wherein each cytosine of each of the synthetic modified RNAs is replaced with 5-methylcytosine and each uracil of each of the synthetic modified RNAs is replaced with pseudouracil, such that iPS cells are obtained.

2. The method of claim 1 , wherein each of the synthetic, modified RNAs encoding OCT4, SOX2, and KLF4 further comprises a 5′ cap.

3. The method of claim 2 , wherein the 5′ cap is a 5′ cap analog.

4. The method of claim 3 , wherein the 5′ cap analog is a 5′ diguanosine cap.

5. The method of claim 1 , wherein each of the synthetic, modified RNAs encoding OCT4, SOX2, and KLF4 does not comprise a 5′ triphosphate.

6. The method of claim 1 , wherein each of the synthetic, modified RNAs encoding OCT4, SOX2, and KLF4 further comprises a poly(A) tail, a Kozak sequence, a 3′ untranslated region, a 5′ untranslated region, or any combination thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: ROSSI, DERRICK
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 047028/0529 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: WARREN, LUIGI
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 047028/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 047183/0563 →
MERGER Recorded Oct 2, 2018
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 047700/0809 →
Continuity (5)
Continuation 14311545 · Jun 23, 2014
Continuation 13088009 · Apr 15, 2011
Provisional Application 61325003 · Apr 16, 2010
Provisional Application 61387220 · Sep 28, 2010
Related Publication 20180216078A1 · Aug 2, 2018